Published online 31 March 2009
Haematologica, Vol 94, Issue 5, 729-732 doi:10.3324/haematol.2008.002063
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Zipperer et al. - Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zipperer, E.
Right arrow Articles by Germing, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zipperer, E.
Right arrow Articles by Germing, U.
Related Collections
Right arrowRelated Article

Myelodysplastic Syndromes

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

Esther Zipperer, Daniela Pelz, Kathrin Nachtkamp, Andrea Kuendgen, Corinna Strupp, Norbert Gattermann, Rainer Haas, Ulrich Germing

Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

Correspondence: Ulrich Germing, Department of Haematology, Oncology and Clinical Immunology Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany. E-mail:Germing{at}med.uni-duesseldorf.de

We studied the impact of comorbidities on survival and evaluated the prognostic utility of comorbidity scores in MDS patients, who received best supportive care and were assessable according to the Charlson Comorbidity Index (CCI) and the Hematopoietic Stem Cell Transplantation Comorbidity Index (HCTCI): 171 patients were identified in the Duesseldorf MDS Registry. The HCTCI captured more comorbidities. Both scoring systems had prognostic relevance, but the HCTCI more clearly distinguished between low-, intermediate- and high-risk patients. Median survival times of the different risk groups according to the HCTCI were 68, 34 and 25 months, respectively. The HCTCI showed prognostic impact in the IPSS intermediate- and high-risk group. On multivariate regression analysis, only the HCTCI remained a prognostic factor independent of IPSS. Considering their prognostic impact, comorbidities of MDS patients should receive appropriate attention in clinical trials as well as day-to-day clinical decision making.

Key words: myelodysplastic syndromes, comorbidity score, prognosis, Charlson Comorbidity Index, International Prognostic Scoring System, Hematopoietic Stem Cell Transplantation Comorbidity Index.


Related Article

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome
Matteo Giovanni Della Porta, Luca Malcovati
Haematologica 2009 94: 602-606. [Full Text] [PDF]